Neuroserpin

Frontiers in Bioscience

Volumn 11, Issue 1 P.1-446, 2006, Pages 33-45

  Galliciotti, Giovanna ^a   Sonderegger, Peter ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Conformational disease; Familial Encephalopathy With Neuroserpin Inclusion Bodies; FENIB; Neural plasticity; Neurodegeneration; Review; Serine protease inhibitor; Serpin

Indexed keywords

EID: 32844457392     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1778     Document Type: Review

References (67)

1. Stoeckli, E. T., P. F. Lemkin, T. B. Kuhn, M. A. Ruegg, M. Heller & P. Sonderegger: Identification of proteins secreted from axons of embryonic dorsal-root-ganglia neurons. Eur J Biochem, 180, 249-58.(1989)
2. Osterwalder, T., J. Contartese, E. T. Stoeckli, T. B. Kuhn & P. Sonderegger: Neuroserpin, an axonally secreted serine protease inhibitor. Embo J, 15, 2944-53.(1996)
3. Silverman, G. A., P. I. Bird, R. W. Carrell, F. C. Church, P. B. Coughlin, P. G. Gettins, J. A. Irving, D. A. Lomas, C. J. Luke, R. W. Moyer, P. A. Pemberton, E. Remold-O'Donnell, G. S. Salvesen, J. Travis & J. C. Whisstock: The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem, 276, 33293-6. Epub 2001 Jul 2.(2001)
4. Schrimpf, S. P., A. J. Bleiker, L. Brecevic, S. V. Kozlov, P. Berger, T. Osterwalder, S. R. Krueger, A. Schinzel & P. Sonderegger: Human neuroserpin (PI12): cDNA cloning and chromosomal localization to 3q26. Genomics, 40, 55-62.(1997)
5. Krueger, S. R., G. P. Ghisu, P. Cinelli, T. P. Gschwend, T. Osterwalder, D. P. Wolfer & P. Sonderegger: Expression of neuroserpin, an inhibitor of tissue plasminogen activator, in the developing and adult nervous system of the mouse. J Neurosci, 17, 8984-96.(1997)
6. Osterwalder, T., A. Kuhnen, W. M. Leiserson, Y. S. Kim & H. Keshishian: Drosophila serpin 4 functions as a neuroserpin-like inhibitor of subtilisin-like proprotein convertases. J Neurosci, 24, 5482-91(2004)
7. Berger, P., S. V. Kozlov, S. R. Krueger & P. Sonderegger: Structure of the mouse gene for the serine protease inhibitor neuroserpin (PI12). Gene, 214, 25-33.(1998)
8. Strandberg, L., D. Lawrence & T. Ny: The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family. Eur J Biochem, 176, 609-16.(1988)
9. McGrogan, M., J. Kennedy, F. Golini, N. Ashton, F. Dunn, K. Bell, E. Tate, R. W. Scott & C. C. Simonsen: Serine Proteases and Their Serpin Inhibitors in the Nervous System. New York (1990)
10. Briand, C., S. V. Kozlov, P. Sonderegger & M. G. Grutter: Crystal structure of neuroserpin: a neuronal serpin involved in a conformational disease. FEBS Lett, 505, 18-22.(2001)
11. Berger, P., S. V. Kozlov, P. Cinelli, S. R. Kruger, L. Vogt & P. Sonderegger: Neuronal depolarization enhances the transcription of the neuronal serine protease inhibitor neuroserpin. Mol Cell Neurosci, 14, 455-67.(1999)
12. Cuadrado, A., C. Navarro-Yubero, H. Furneaux, J. Kinter, P. Sonderegger & A. Munoz: HuD binds to three AU-rich sequences in the 3′-UTR of neuroserpin mRNA and promotes the accumulation of neuroserpin mRNA and protein. Nucleic Acids Res, 30, 2202-11.(2002)
13. Navarro-Yubero, C., A. Cuadrado, P. Sonderegger & A. Munoz: Neuroserpin is post-transcriptionally regulated by thyroid hormone. Brain Res Mol Brain Res, 123, 56-65.(2004)
14. Hastings, G. A., T. A. Coleman, C. C. Haudenschild, S. Stefansson, E. P. Smith, R. Barthlow, S. Cherry, M. Sandkvist & D. A. Lawrence: Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J Biol Chem, 272, 33062-7.(1997)
15. Saito, S., R. Matoba, N. Ueno, K. Matsubara & K. Kato: Comparison of gene expression profiling during postnatal development of mouse dentate gyrus and cerebellum. Physiol Genomics, 8, 131-7. Epub 2002 Jan 15.(2002)
16. Matoba, R., S. Saito, N. Ueno, C. Maruyama, K. Matsubara & K. Kato: Gene expression profiling of mouse postnatal cerebellar development. Physiol Genomics, 4, 155-164.(2000)
17. Teesalu, T., A. Kulla, A. Simisker, V. Siren, D. A. Lawrence, T. Asser & A. Vaheri: Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system. Thromb Haemost, 92, 358-68(2004)
18. Hill, R. M., P. K. Parmar, L. C. Coates, E. Mezey, J. F. Pearson & N. P. Birch: Neuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AtT-20 cells. Biochem J, 345 Pt 3, 595-601.(2000)
19. Parmar, P. K., L. C. Coates, J. F. Pearson, R. M. Hill & N. P. Birch: Neuroserpin regulates neurite outgrowth in nerve growth factor-treated PC12 cells. J Neurochem, 82, 1406-15.(2002)
20. Hakak, Y., J. R. Walker, C. Li, W. H. Wong, K. L. Davis, J. D. Buxbaum, V. Haroutunian & A. A. Fienberg: Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A, 98, 4746-51.(2001)
21. Prolla, T. A.: DNA microarray analysis of the aging brain. Chem Senses, 27, 299-306.(2002)
22. Lotem, J., H. Gal, R. Kama, N. Amariglio, G. Rechavi, E. Domany, L. Sachs & D. Givol: Inhibition of p53-induced apoptosis without affecting expression of p53-regulated genes. Proc Natl Acad Sci U S A, 100, 6718-23. Epub 2003 May 12.(2003)
23. Lilla, V., G. Webb, K. Rickenbach, A. Maturana, D. F. Steiner, P. A. Halban & J. C. Irminger: Differential gene expression in well-regulated and dysregulated pancreatic beta-cell (MIN6) sublines. Endocrinology, 144, 1368-79.(2003)
24. Sonna, L. A., M. L. Cullivan, H. K. Sheldon, R. E. Pratt & C. M. Lilly: Effect of hypoxia on gene expression by human hepatocytes (HepG2). Physiol Genomics, 12, 195-207. Epub 2002 Dec 3.(2003)
25. Ghannam, G., A. Takeda, T. Camarata, M. A. Moore, A. Viale & N. R. Yaseen: The oncogene Nup98-HOXA9 induces gene transcription in myeloid cells. J Biol Chem, 279, 866-75. Epub 2003 Oct 15.(2004)
26. Tavor, S., D. J. Park, S. Gery, P. T. Vuong, A. F. Gombart & H. P. Koeffler: Restoration of C/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation. J Biol Chem, 278, 52651-9. Epub 2003 Sep 29.(2003)
27. Brar, A. K., S. Handwerger, C. A. Kessler & B. J. Aronow: Gene induction and categorical reprogramming during in vitro human endometrial fibroblast decidualization. Physiol Genomics, 7, 135-48. Epub 2001 Sep 21.(2001)
28. Reimer, T., D. Koczan, B. Gerber, D. Richter, H. J. Thiesen & K. Friese: Microarray analysis of differentially expressed genes in placental tissue of pre-eclampsia: up-regulation of obesity-related genes. Mol Hum Reprod, 8, 674-80.(2002)
29. Chennathukuzhi, V., J. M. Stein, T. Abel, S. Donlon, S. Yang, J. P. Miller, D. M. Allman, R. A. Simmons & N. B. Hecht: Mice deficient for testis-brain RNA-binding protein exhibit a coordinate loss of TRAX, reduced fertility, altered gene expression in the brain, and behavioral changes. Mol Cell Biol, 23, 6419-34.(2003)
30. Rouger, K., M. Le Cunff, M. Steenman, M. C. Potier, N. Gibelin, C. A. Dechesne & J. J. Leger: Global/temporal gene expression in diaphragm and hindlimb muscles of dystrophin-deficient (mdx) mice. Am J Physiol Cell Physiol, 283, C773-84.(2002)
31. Greenwell-Wild, T., N. Vazquez, D. Sim, M. Schito, D. Chatterjee, J. M. Orenstein & S. M. Wahl: Mycobacterium avium infection and modulation of human macrophage gene expression. J Immunol, 169, 6286-97.(2002)
32. Vawter, M. P., C. Shannon Weickert, E. Ferran, M. Matsumoto, K. Overman, T. M. Hyde, D. R. Weinberger, W. E. Bunney & J. E. Kleinman: Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia. Neurochem Res, 29, 1245-55(2004)
33. Lewis, D. A. & J. A. Lieberman: Catching up on schizophrenia: natural history and neurobiology. Neuron, 28, 325-34.(2000)
34. Koubova, J. & L. Guarente: How does calorie restriction work? Genes Dev, 17, 313-21.(2003)
35. Osterwalder, T., P. Cinelli, A. Baici, A. Pennella, S. R. Krueger, S. P. Schrimpf, M. Meins & P. Sonderegger: The axonally secreted serine proteinase inhibitor, neuroserpin, inhibits plasminogen activators and plasmin but not thrombin. J Biol Chem, 273, 2312-21.(1998)
36. Barker-Carlson, K., D. A. Lawrence & B. S. Schwartz: Acyl-enzyme complexes between tissue-type plasminogen activator and neuroserpin are short-lived in vitro. J Biol Chem, 277, 46852-7. Epub 2002 Sep 11.(2002)
37. Cinelli, P., R. Madani, N. Tsuzuki, P. Vallet, M. Arras, C. N. Zhao, T. Osterwalder, T. Rulicke & P. Sonderegger: Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol Cell Neurosci, 18, 443-57.(2001)
38. Zhang, Z., L. Zhang, M. Yepes, Q. Jiang, Q. Li, P. Arniego, T. A. Coleman, D. A. Lawrence & M. Chopp: Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation, 106, 740-5.(2002)
39. Yepes, M., M. Sandkvist, M. K. Wong, T. A. Coleman, E. Smith, S. L. Cohan & D. A. Lawrence: Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood, 96, 569-76.(2000)
40. Yepes, M., M. Sandkvist, T. A. Coleman, E. Moore, J. Y. Wu, D. Mitola, T. H. Bugge & D. A. Lawrence: Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest, 109, 1571-8.(2002)
41. Yepes, M., M. Sandkvist, E. G. Moore, T. H. Bugge, D. K. Strickland & D. A. Lawrence: Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest, 112, 1533-40.(2003)
42. Pittman, R. N. & A. J. DiBenedetto: PC12 cells overexpressing tissue plasminogen activator regenerate neurites to a greater extent and migrate faster than control cells in complex extracellular matrix. J Neurochem, 64, 566-75.(1995)
43. Madani, R., S. Kozlov, A. Akhmedov, P. Cinelli, J. Kinter, H. P. Lipp, P. Sonderegger & D. P. Wolfer: Impaired explorative behavior and neophobia in genetically modified mice lacking or overexpressing the extracellular serine protease inhibitor neuroserpin. Mol Cell Neurosci, 23, 473-94.(2003)
44. Wannier-Morino, P., G. Rager, P. Sonderegger & D. Grabs: Expression of neuroserpin in the visual cortex of the mouse during the developmental critical period. Eur J Neurosci, 17, 1853-60.(2003)
45. Gettins, P. G.: Serpin structure, mechanism, and function. Chem Rev, 102, 4751-804.(2002)
46. Makarova, A., I. Mikhailenko, T. H. Bugge, K. List, D. A. Lawrence & D. K. Strickland: The low density lipoprotein receptor-related protein modulates protease activity in the brain by mediating the cellular internalization of both neuroserpin and neuroserpin-tissue-type plasminogen activator complexes. J Biol Chem, 278, 50250-8. Epub 2003 Sep 30.(2003)
47. Kounnas, M. Z., F. C. Church, W. S. Argraves & D. K. Strickland: Cellular internalization and degradation of antithrombin III-thrombin, heparin cofactor II-thrombin, and alpha 1-antitrypsin-trypsin complexes is mediated by the low density lipoprotein receptor-related protein. J Biol Chem, 271, 6523-9.(1996)
48. Vivien, D. & A. Buisson: Serine protease inhibitors: novel therapeutic targets for stroke? J Cereb Blood Flow Metab, 20, 755-64.(2000)
49. Stapf, C. & J. P. Mohr: Ischemic stroke therapy. Annu Rev Med, 53, 453-75.(2002)
50. Gladstone, D. J. & S. E. Black: Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice. Cmaj, 165, 311-7.(2001)
51. Wang, Y. F., S. E. Tsirka, S. Strickland, P. E. Stieg, S. G. Soriano & S. A. Lipton: Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med, 4, 228-31.(1998)
52. Nagai, N., M. De Mol, H. R. Lijnen, P. Carmeliet & D. Collen: Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation, 99, 2440-4.(1999)
53. Liang, W., L. Chuan-Zhen, D. Qiang, Q. Jian, R. Hui-Min & X. Bao-Guo: Reductions in mRNA of the neuroprotective agent, neuroserpin, after cerebral ischemia/reperfusion in diabetic rats. Brain Res, 1015, 175-80(2004)
54. Pawlak, R. & S. Strickland: Tissue plasminogen activator and seizures: a clot-buster's secret life. J Clin Invest, 109, 1529-31.(2002)
55. Chang, W. S., N. T. Chang, S. C. Lin, C. W. Wu & F. Y. Wu: Tissue-specific cancer-related serpin gene cluster at human chromosome band 3q26. Genes Chromosomes Cancer, 29, 240-55.(2000)
56. Hasumi, H., H. Ishiguro, M. Nakamura, S. Sugiura, Y. Osada, Y. Miyoshi, K. Fujinami, M. Yao, K. Hamada, H. Yamada-Okabe, Y. Kubota & H. Uemura: Neuroserpin (PI-12) is upregulated in high-grade prostate cancer and is associated with survival. Int J Cancer, 115, 911-6(2005)
57. Davis, R. L., A. E. Shrimpton, P. D. Holohan, C. Bradshaw, D. Feiglin, G. H. Collins, P. Sonderegger, J. Kinter, L. M. Becker, F. Lacbawan, D. Krasnewich, M. Muenke, D. A. Lawrence, M. S. Yerby, C. M. Shaw, B. Gooptu, P. R. Elliott, J. T. Finch, R. W. Carrell & D. A. Lomas: Familial dementia caused by polymerization of mutant neuroserpin. Nature, 401, 376-9.(1999)
58. Davis, R. L., A. E. Shrimpton, R. W. Carrell, D. A. Lomas, L. Gerhard, B. Baumann, D. A. Lawrence, M. Yepes, T. S. Kim, B. Ghetti, P. Piccardo, M. Takao, F. Lacbawan, M. Muenke, R. N. Sifers, C. B. Bradshaw, P. F. Kent, G. H. Collins, D. Larocca & P. D. Holohan: Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet, 359, 2242-7.(2002)
59. Takao, M., M. D. Benson, J. R. Murrell, M. Yazaki, P. Piccardo, F. W. Unverzagt, R. L. Davis, P. D. Holohan, D. A. Lawrence, R. Richardson, M. R. Farlow & B. Ghetti: Neuroserpin mutation S52R causes neuroserpin accumulation in neurons and is associated with progressive myoclonus epilepsy. J Neuropathol Exp Neurol, 59, 1070-86.(2000)
60. Bradshaw, C. B., R. L. Davis, A. E. Shrimpton, P. D. Holohan, C. B. Rea, D. Fieglin, P. Kent & G. H. Collins: Cognitive deficits associated with a recently reported familial neurodegenerative disease: familial encephalopathy with neuroserpin inclusion bodies. Arch Neurol, 58, 1429-34.(2001)
61. Davis, R. L., P. D. Holohan, A. E. Shrimpton, A. H. Tatum, J. Daucher, G. H. Collins, R. Todd, C. Bradshaw, P. Kent, D. Feiglin, A. Rosenbaum, M. S. Yerby, C. M. Shaw, F. Lacbawan & D. A. Lawrence: Familial encephalopathy with neuroserpin inclusion bodies. Am J Pathol, 155, 1901-13.(1999)
62. Yazaki, M., J. J. Liepnieks, J. R. Murrell, M. Takao, B. Guenther, P. Piccardo, M. R. Farlow, B. Ghetti & M. D. Benson: Biochemical characterization of a neuroserpin variant associated with hereditary dementia. Am J Pathol, 158, 227-33.(2001)
63. Belorgey, D., L. K. Sharp, D. C. Crowther, M. Onda, J. Johansson & D. A. Lomas: Neuroserpin Portland (Ser52Arg) is trapped as an inactive intermediate that rapidly forms polymers: implications for the epilepsy seen in the dementia FENIB. Eur J Biochem, 271, 3360-7(2004)
64. Miranda, E., K. Romisch & D. A. Lomas: Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum. J Biol Chem, 16, 16(2004)
65. Belorgey, D., D. C. Crowther, R. Mahadeva & D. A. Lomas: Mutant Neuroserpin (S49P) that causes familial encephalopathy with neuroserpin inclusion bodies is a poor proteinase inhibitor and readily forms polymers in vitro. J Biol Chem, 277, 17367-73. Epub 2002 Mar 5.(2002)
66. Onda, M., D. Belorgey, L. K. Sharp & D. A. Lomas: Latent S49P neuroserpin forms polymers in the dementia familial encephalopathy with neuroserpin inclusion bodies. J Biol Chem, 280, 13735-41(2005)
67. Lomas, D. A. & R. W. Carrell: Serpinopathies and the conformational dementias. Nat Rev Genet, 3, 759-68,(2002)